ClinicalTrials.gg
RecruitingNCT06869551Updated Oct 6, 2026

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

A Phase 3 interventional study of Deucravacitinib and Placebo in Juvenile Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Recruiting at 48 sites in 11 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Oct 6, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Arthritis, Juvenile with a site in Brazil — 6 open to participants now, 9 under way, 5 of them phase 3. Arthritis, Juvenile · Brazil.

Planned enrollment
26th of 32
60 · median 181
Started
2025
the only one that year
Phase 3
22 of 34
4 open now
Registered
33rd of 34
by date
Lead sponsor
4 of 34
Bristol-Myers Squibb

Among the 34 studies in Arthritis, Juvenile with a site in Brazil, this one is the 26th largest by planned enrollment of the 32 interventional ones that give a count, is the only one that started in 2025, is one of 22 in phase 3, and was the 33rd registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

6 of the 34 studies in Arthritis, Juvenile with a site in Brazil are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Juvenile with a site in Brazil, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

03

Conditions studied

  • Juvenile Psoriatic Arthritis

Browse trials for

Keywords

  • Juvenile Psoriatic Arthritis (JPsA)
  • Juvenile Idiopathic Arthritis (JIA)
  • Pediatric PsA
  • Deucravacitinib
  • BMS-986165
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
  • Participants must have at least three joints that are affected by arthritis.
  • Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.

Exclusion criteria

Exclusion Criteria

  • Participants must not have been diagnosed with JPsA before 5 years of age.
  • Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
  • Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: Deucravacitinib

  • Placebo comparator
    Arm B

    Drug: Deucravacitinib · Other: Placebo

Interventions

  • Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Time to first flare during the withdrawal period

    Time frame: From week 16 up to week 42

Secondary outcomes

  1. Trough concentration at steady state (Cminss)

    Time frame: At week 16

  2. Time-averaged steady-state concentration (Cavgss)

    Time frame: At week 16

  3. Steady-state maximum observed concentration (Cmaxss)

    Time frame: At week 16

  4. Number of participants with flare during the withdrawal period

    Time frame: From week 16 up to week 42

  5. Number of participants achieving low disease activity (Juvenile arthritis disease activity 71-joint score based on C-reactive protein (JADAS71-CRP) score: for oligoarthritis 1.1 to 2; for polyarthritis 1.1 to 3.8)

    Time frame: Through week 16 and up to week 42

  6. Number of participants achieving inactive disease (JADAS71-CRP score ≤ 1)

    Time frame: Through week 16 and up to week 42

  7. Number of participants attaining clinical remission for at least 6 consecutive months

    Time frame: At week 42

  8. Number of participants achieving psoriasis area and severity index (PASI) 75

    Time frame: At week 42

  9. Number of participants with adverse events (AEs)

    Time frame: Up to week 42

  10. Number of participants with adverse event of special interest (AESIs)

    Time frame: Up to week 42

  11. Number of participants with AEs leading to discontinuation

    Time frame: Up to week 42

  12. Number of participants with serious adverse events (SAEs)

    Time frame: Up to week 42

  13. Number of participants with Uveitis

    Time frame: Up to week 42

  14. Number of participants achieving each of juvenile idiopathic arthritis-American College of Rheumatology (JIA-ACR) (30/50/70/90)

    Time frame: Through week 16 and up to week 42

  15. Change from baseline in juvenile idiopathic arthritis-American College of Rheumatology (JIA-ACR) Core Criteria

    Time frame: Through week 16 and up to week 42

  16. Number of participants for each assessment who evaluate palatability scale as ≥ 3 (good or better), swallowability scale as ≤ 4 (neutral or easier), and taste scales (Sweetness, Bitterness, Flavor, and Overall Taste) as "None" or "Weak"

    Time frame: At week 16

  17. Assessment of exposure-response (E-R) utilizing steady-state exposure of deucravacitinib from the pharmacokinetic (PK) analysis and efficacy results using JIA-ACR 30

    Time frame: At week 16

07

Study locations

29 of 48 sites recruiting
  • Local Institution - 0038
    Lancaster, California 93534, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0020
    Chicago, Illinois 60611, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0023
    Indianapolis, Indiana 46202, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0059
    North New Hyde Park, New York 11040, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0065
    Cincinnati, Ohio 45229, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0066
    Cleveland, Ohio 44109, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0036
    Austin, Texas 78723, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Centro de Oncologia Leonardo Da Vinci - ATO Terapias
    Fortaleza, Ceará 60140-025, Brazil
    Recruiting
    • Miria Cavalcante, Site 0068 · Contact+558532240552
  • Local Institution - 0032
    Cuiabá, Mato Grosso 78020-500, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Santa Casa de Misericordia de Belo Horizonte
    Belo Horizonte, Minas Gerais 30150-221, Brazil
    Recruiting
    • Filipe Maciel, Site 0030 · Contact+5531984545405
  • Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à Infância
    Curitiba, Paraná 80250-060, Brazil
    Recruiting
    • Marcia Bandeira, Site 0072 · Contact4133101356
  • Local Institution - 0013
    Curitiba, Paraná 80250-060, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Das Clinicas Ufpe
    Recife, Pernambuco 50670-420, Brazil
    Recruiting
    • André Cavalcanti, Site 0007 · Contact+5581999983400
  • Local Institution - 0033
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • LMK Serviços Médicos S/S
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
    Recruiting
    • maria Picarelli, Site 0008 · Contact5551999897478
  • Hospital Lifeplus Litoral Norte
    Xangri-lá, Rio Grande do Sul 95588-000, Brazil
    Recruiting
    • Penelope Esther Palominos, Site 0069 · Contact
  • PSEG- Pesquisa Clínica
    Vila Clementino, São Paulo-SP 04038-002, Brazil
    Recruiting
    • Maria Victoria Suarez Restrepo, Site 0073 · Contact11974912009
  • Local Institution - 0027
    Rio de Janeiro, 21941-612, Brazil
    Not yet recruiting
    • Site 0027 · Contact
  • Santa Casa Instituto de Pesquisa
    São Paulo, 01223-001, Brazil
    Recruiting
    • Maria dos Santos, Site 0047 · Contact11996588290
  • Local Institution - 0010
    São Paulo, 04022-001, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD
    Plovdiv, 4002, Bulgaria
    Recruiting
    • Krastina Stefanova-Kelly, Site 0054 · Contact+359876324578
  • Medical Center for Specialized Medical Care of Cardiovascular Diseases
    Sofia, 1309, Bulgaria
    Recruiting
    • Stefan Stefanov, Site 0077 · Contact
  • Local Institution - 0062
    Sofia, 1797, Bulgaria
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0074
    Beijing, Beijing Municipality 100020, China
    Not yet recruiting
    • Site 0074 · Contact
  • Local Institution - 0049
    Beijing, Beijing Municipality 100045, China
    Not yet recruiting
    • Site 0049 · Contact
  • The Children's Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400065, China
    Recruiting
    • Xuemei Tang, Site 0056 · Contact13012352441
  • Guangzhou Women and Children's Medical Center
    Guangzhou, Guangdong 510000, China
    Recruiting
    • Ping Zeng, Site 0060 · Contact+8613160897678
  • Childrens Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210008, China
    Recruiting
    • Haiguo Yu, Site 0052 · Contact111111
  • The First Hospital of Jilin University
    Changchun, Jilin 130000, China
    Recruiting
    • sirui yang, Site 0053 · Contact13500889222
  • The Children's Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310057, China
    Recruiting
    • Meiping Lu, Site 0051 · Contact13685773988
  • Children's Hospital of Fudan University
    Shanghai, 201102, China
    Recruiting
    • Li Sun, Site 0050 · Contact862164931122
  • Fakultni nemocnice Olomouc
    Olomouc, Olomouc Region 779 00, Czechia
    Recruiting
    • Katerina Bouchalova, Site 0003 · Contact+420602668887
  • Fakultni nemocnice v Motole
    Prague, Praha 5 150 06, Czechia
    Recruiting
    • Rudolf Horvath, Site 0002 · Contact420727812317
  • Kinderklinik des Uni-Klinikums Erlangen
    Erlangen, 91054, Germany
    Recruiting
    • Tobias Krickau, Site 0063 · Contact091318533118
  • Praxis Kinder- und Jugendrheumatologie Dr. Ivan Foeldvari
    Hamburg, 22081, Germany
    Recruiting
    • Ivan Foeldvari, Site 0026 · Contact00494020923698
  • University of Naples Federico II
    Naples, Campania 80131, Italy
    Recruiting
    • Roberta Naddei, Site 0005 · Contact00393272022085
  • Azienda Ospedaliera Universitaria Meyer IRCCS
    Florence, Tuscany 50139, Italy
    Recruiting
    • Gabriele Simonini, Site 0004 · Contact+393297973141
  • Local Institution - 0017
    San Juan, 00917, Puerto Rico
    Withdrawn

    Not enrolling at this site — choose another above.

  • Spitalul Clinic de Urgenta pentru Copii Cluj-Napoca
    Cluj-Napoca, Cluj 400177, Romania
    Recruiting
    • Mihaela Sparchez, Site 0067 · Contact+40723400453
  • Local Institution - 0048
    Iași, Iaşi 700135, Romania
    Withdrawn

    Not enrolling at this site — choose another above.

  • Sc Medaudio-Optica Srl
    Râmnicu Vâlcea, Vâlcea County 247065, Romania
    Recruiting
    • RAZVAN IONITESCU, Site 0040 · Contact0040722557297
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona [Barcelona] 08035, Spain
    Recruiting
    • Mireia Corbeto, Site 0046 · Contact667517630
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid, Comunidad de 28034, Spain
    Recruiting
    • Alina Lucica Boteanu, Site 0041 · Contact+34913368571
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
    Recruiting
    • LUCIA LACRUZ PEREZ, Site 0042 · Contact+34961244792
  • Istanbul Universitesi Cerrahpasa
    Istanbul- Fatih, Istanbul 34098, Turkey (Türkiye)
    Recruiting
    • Ozgur Kasapcopur, Site 0043 · Contact+905322129111
  • Local Institution - 0061
    Ankara, 06170, Turkey (Türkiye)
    Not yet recruiting
    • Site 0061 · Contact
  • Local Institution - 0044
    Ankara, 06230, Turkey (Türkiye)
    Not yet recruiting
    • Site 0044 · Contact
  • Umraniye Training and Research Hospital
    Istanbul, 34766, Turkey (Türkiye)
    Recruiting
    • Betul Sozeri, Site 0045 · Contact+905327629003
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2030, 59 months after the start.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's planned 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 11, 2025
StartActual
Mar 13, 2025
Primary completionEst.
Mar 6, 2030
CompletionEst.
Mar 4, 2031
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 Brazil, 1 Bulgaria)
  • Hospital Lifeplus Litoral Norte · Xangri-lá, Brazil
  • Medical Center for Specialized Medical Care of Cardiovascular Diseases · Sofia, Bulgaria
Show 1 removed
  • Local Institution - 0069 · Sofia, Bulgaria
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Brazil, 1 Bulgaria)
    • Hospital Lifeplus Litoral Norte · Xangri-lá, Brazil
    • Medical Center for Specialized Medical Care of Cardiovascular Diseases · Sofia, Bulgaria
    Show 1 removed
    • Local Institution - 0069 · Sofia, Bulgaria
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06869551
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Mar 13, 2025
Primary completion
Mar 6, 2030 (estimated)
Completion
Mar 4, 2031 (estimated)
Last update
Oct 6, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion